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LIST OF ABBREVIATIONS 	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SUMMARY 	  
Immune responses within the central nervous system (CNS), welcome or 
undesired, need to be tightly controlled to protect the CNS tissue from 
irreparable damage. One of our major interests during the last years was to 
study the immunoregulatory properties of infiltrating antigen-presenting cells 
(APCs) and resident glial cells in controlling T cell effector functions within the 
CNS in the context of glioblastoma (GB) and multiple sclerosis (MS). We 
focused on B7:CD28 co-stimulatory pathways, given that interrupting the 
signaling events are attractive strategies to either enhance tumor 
immunogenicity or control autoimmune inflammation. 
GB is a highly aggressive brain cancer that is known for its ability to evade 
eradication by the immune system. The GB microenvironment actively 
suppresses effective anti-tumor responses by multiple mechanisms, and we 
hypothesized that the expression of immune inhibitory B7 family molecules 
might be one of them (study I and II). We could show particularly that high 
levels of PD-L1 were detectable in all human GB tissue samples examined 
but not in normal brain regions adjacent to tumor tissue. Alloreactive co-
culture assays pointed to a strong inhibitory function of GB-associated PD-L1 
on T-cell activation. Our results suggested that PD-L1:PD1 interactions were 
involved in GB-mediated immune suppression and thus represented a 
promising therapeutic target. These findings have been confirmed by others 
and clinical trials evaluating blockers of PD-L1 and its receptor PD-1 in GB 
patients are underway. 
In contrast to anti-GB therapies, enhancing local immunosuppressive 
properties within the brain is desirable in autoimmune neuroinflammatory 
diseases such as MS. Manipulation of PD-L1:PD1 interactions may provide a 
means to control self-reactive T cell activation and effector functions in the 
CNS. We have found that PD-L1 expression on human monocytes from the 
peripheral blood was upregulated by the approved MS drug interferon (IFN)-ß 
and led to reduced APC functions in vitro (study III). Moreover, IFN-ß 
treatment elevated PD-L1 levels in MS patients indicating that its anti-
inflammatory effects can involve modulation of PD-L1 expression. Further 
work demonstrated an inhibitory role for PD-L1 on different monocyte-derived, 
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CNS-infiltrating APC populations and resident microglia in regulating myelin-
reactive T-cell activation in experimental MS models (experimental 
autoimmune encephalomyelitis, EAE; study IV). Taken together, our data 
demonstrated that B7-H1:PD-1 interactions diminished autoreactive T cell 
responses and restricted immunopathological damage in the CNS. 
We then explored how glial cells contribute to the tissue homeostasis of the 
healthy CNS beyond APC functions and co-inhibition, concentrating on 
astrocytes. It was reported that astrocytes could promote neuronal survival in 
co-culture experiments, however the in vivo relevance and molecular 
mechanisms involved in the adult CNS remained unclear. By conditional, 
astrocyte-restricted protein synthesis termination, we found that selective 
paralysis of glial fibrillary acidic protein (GFAP)+ astrocytes in vivo led to rapid 
neuronal cell loss and severe motor deficits that were independent of 
microglial bystander activation (study V). Instead, we identified the redox 
scavenging capabilities of the astroglial cell pool as a critical factor for 
maintaining neuronal health in the adult CNS. 
 
The work presented here improves our understanding of immunoregulatory 
and steady state functions of the CNS glial environment and may aid in the 
design of therapeutic strategies to limit nervous tissue injury. 
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INTRODUCTION 	  
Glial cell types: Spotlight on microglia and astrocytes 	  
The term ‘Nervenkitt’ (i.e. nerve-putty) was first introduced by the pathologist 
Rudolf Virchow in the 1850s, picturing neuroglia as connective tissue that fills 
up all interstices among nerve cells and their fibers (reviewed in (1)). Although 
most glial cell types and neurons arise from the same embryonic precursor 
cell, glial cells differ from neurons morphologically and functionally. They do 
not have the same membrane properties and do not electrically signal like 
neurons (2). Glial cells are a heterogeneous population (reviewed in (3)), and 
are classified as microglia or macroglia which consist of astrocytes, myelin-
forming oligodendrocytes in the CNS and Schwann cells in the peripheral 
nervous system. 
Microglia. Microglia are the resident macrophages of the CNS parenchyma 
that constitute approximately 5-12% of brain cells depending on the region 
studied (4). In contrast to CNS macrophages that are found in the meninges, 
choroid plexus and perivascular space, microglia are ontogenically distinct as 
they originate from primitive, yolk sac-derived myeloid progenitors that 
migrate to the neural tube during early development (5, 6). Studies using bone 
marrow chimeric animals indicate that the mature microglia pool is maintained 
independently of recruitment of bone marrow-derived monocytes from the 
circulation and expands locally even after brain injuries (7-9). In addition to 
more fundamental roles in clearing dead cells and debris, microglia have also 
been implicated in synaptic remodeling as they can engulf and remove 
inappropriate synaptic connections (10, 11). 
Microglia are activated in many neuroinflammatory and -degenerative 
diseases, and the outcome of this activation may be beneficial, deleterious or 
neutral (reviewed in (12)). Microglial activation leads to disease-associated 
gene expression (13-15) and relatively uniform morphological changes 
converting from a ramified appearance with fine branching processes to an 
amoeboid shape. In EAE, a mouse model of MS, recent studies support the 
concept that infiltrating monocyte-derived macrophages/myeloid cells and 
resident microglia perform non-overlapping functions in the inflamed CNS (7, 
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15). Yamasaki et al. used a dual reporter system to discriminate between 
CCR2 (RFP)+ monocyte-derived macrophages and CX3CR1 (GFP)+ microglia 
cells. They showed that monocyte-derived macrophages were highly 
inflammatory and phagocytic, initiating demyelination at nodes of Ranvier, 
whereas microglia appeared relatively inert at disease onset (15). Whether 
this is pathogenetically relevant for MS patients is currently unclear. 
Astrocytes. Astrocytes descend from neuroepithelial stem cells and are 
another group of specialized glial cells that are plentiful in the CNS. Their 
extended processes form gap junctions with each other, contact synapses 
and nodes of Ranvier and can also ensheath blood vessels. During 
development, astrocyte-derived molecules such as glypicans appear to 
regulate synaptogenesis (16). It has been proposed that astrocytes have 
essential ‘housekeeping’ functions in the healthy adult CNS, including the 
maintenance of a viable nervous system environment for neurons and the 
regulation of synaptic transmission and blood flow (reviewed in (17, 18). Much 
of what we know about astrocyte function today has come from in vitro studies 
using isolated glial cells or slice cultures, where they among others promote 
growth and survival of neurons (19). However, global deletion (knockout) of 
astrocyte intermediate filament genes such as GFAP and vimentin, resulted in 
no gross neurological, behavioral, or structural CNS abnormalities in vivo (20, 
21). Similar to the studies of microglia biology, advances in transgenic 
technologies and imaging techniques have begun to allow us to dissect the in 
vivo role of astrocytes in the nervous system function in more detail. 
Astrocytes can, like microglia, respond to pathological stimuli through reactive 
gliosis (reviewed in (22)), which might be help- or harmful in several disorders 
of the nervous system. For example, in chronic brain lesions of individuals 
with MS, reactive astrocytes form a glial scar (23). Several recent loss-of-
function studies in EAE indicate that they thereby can restrict the spread of 
inflammatory cells within CNS tissue, but on the other hand astrocytes might 
contribute to attracting leukocytes at earlier disease stages (24-26). In the 
setting of spinal cord injury, the glial scar can act as a barrier to the 
regeneration of damaged nerve fibers (27). Moreover, astrocytes are likely 
important contributors to neurodegenerative diseases such as familial 
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amyotrophic lateral sclerosis (fALS) (28), and can become cancerous, giving 
rise to gliomas. 	  
The concept of the CNS ‘immune privilege’ 	  
The concept of ‘immune privilege’ of the CNS has a long history (29, 30). It is 
based on the observation that immunogens such as xenografts, bacteria, 
viruses/adenoviral vectors evade immune recognition relative to other organs, 
when microinjected into the CNS parenchyma. However, peripheral 
immunization with the same immunogen is followed by a brisk immune 
response to the antigen deposited within the CNS. The supposed reason for 
this exceptional position of the CNS is a survival advantage by protecting 
delicate post-mitotic neurons from inflammatory damage. In addition, 
pathogens usually enter the CNS from a peripheral site where they already 
initiated an immune response in the draining lymph nodes and spleen. The 
term CNS ‘privilege’ does not relate to the complete absence of 
immunological components, but rather the CNS and the immune system are 
tightly coupled and regulated (30). 
The cellular basis of CNS ‘immune privilege’ is amongst others the blood-
brain barrier (BBB), which excludes plasma proteins, immune cells and their 
associated inflammatory molecules from the healthy CNS (31, 32). In addition, 
parenchymal dendritic cells (DCs) delivering antigen to the cervical lymph 
nodes are lacking in the uninflamed brain, although DCs are present in the 
meninges and the choroid plexus (33). This changes once inflammation is 
established and the ‘immune privilege’ is undermined. For example, it has 
been shown that mostly peripherally derived DCs accumulate in the brains 
and spinal cords of mice with proteolipid protein (PLP) peptide-induced EAE, 
where they might prime naïve T cells specific for a different PLP peptide 
locally (leading to epitope spreading (34, 35)). Soluble antigen drainage from 
the CNS to deep cervical lymph nodes occurs as well, and two very recent 
reports have just reignited the debate if vessels that fulfill the criteria of a 
lymphatic system are really absent in the CNS (36, 37). 
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Several studies indicate that the CNS resident cells and their 
microenvironment have immunosuppressive properties during steady state 
and can actively participate in shaping the immune response within the 
inflamed CNS. Neurons can inhibit microglial activation in several ways 
including both cell contact-dependent receptor-ligand interaction (for example 
membrane-bound CD200 and its receptor (38), TREM2-DAP12 (39) and 
others) and secreted molecules (such as soluble fractalkine and its microglial 
receptor CX3CR1 (40), reviewed in (41)). Transforming growth factor β1 
(TGF-ß1) is a pleiotropic cytokine with potent immunosuppressive and 
neurotrophic properties that is expressed at low levels by both neurons and 
glial cells in the normal CNS, but is upregulated in the inflamed brain (42, 43). 
TGF-β1 has been shown to inhibit microglial and astrocyte activation (44-46). 
Moreover, in vivo, microglia (and astrocytes) express relatively low levels of 
major histocompatibility complex (MHC) class II and other accessory 
molecules that are required for efficient antigen presentation to T cells 
(reviewed in (47)). In addition, microglia and astrocytes produce factors that 
might directly regulate T cells within the CNS parenchyma (reviewed in (48)): 
For example, using astrocyte-T cell co-cultures it was reported, that 
astrocytes can suppress T cell proliferation (partially by prostaglandins (49)), 
induce T cell apoptosis (50) or regulatory T cells (Tregs (51)). Gimsa et al. 
proposed astrocyte-induced up-regulation of the inhibitory molecule cytotoxic 
T lymphocyte antigen-4 (CTLA-4) on activated T cells as another 
immunosuppressive mechanism within the CNS glial environment (52). 	  
The B7 family of co-stimulatory molecules 	  
In order to allow T cells to recognize and respond to an antigen it has to be 
processed and presented on the surface of an APC in the context of MHC 
complexes. T cells require additional positive signals from APCs for their 
activation and survival that is provided by co-stimulatory receptor-ligand pairs 
(signal 2), including the well-characterized B7:CD28 system (53) and 
inflammatory cytokines (signal 3). The B7:CD28 family members have key 
roles in regulating T cell activation and tolerance. B7-1 (CD80) and B7-2 
(CD86) expressed by APCs have a dual specificity for the stimulatory receptor 
	   12 
CD28 on T cells, and the inhibitory CTLA-4 (CD152) that down-regulates T 
cell responses (54). More recently discovered B7 family members such as 
ICOSL and PD-L1 (B7-H1) and PD-L2 (B7-DC) are not only expressed on 
professional APCs (DCs, macrophages, B cells) but also on parenchymal 
cells within non-lymphoid organs (reviewed in (55, 56)). 
The ICOSL:ICOS pathway. ICOSL has been detected on the surface of 
professional APCs, and other non-immune cell types such as fibroblasts, 
endothelial and some epithelial cells (57-59). This expression pattern 
suggests that the outcome of ICOSL:ICOS interactions during immune 
responses depends not only on their timing but also on the tissue environment 
(55). ICOS is a CD28 homologue and ‘inducible co-stimulator’ that is 
expressed on T cells after stimulation by the T cell receptor (60). ICOSL:ICOS 
interactions are important in promoting effective T helper cell (TH) and B cell 
responses. The phenotype of 9 patients with common variable 
immunodeficiency (CVID) lacking ICOS expression on T cells because of an 
inherited homozygous deletion in the ICOS gene indicates its critical 
involvement in T cell help to B cells (61, 62). Moreover, ICOS-deficient mice 
have abnormal germinal center formation in the spleen and immunoglobulin 
class switching is defective (63, 64). In the absence of ICOS during the 
priming phase of EAE, disease severity is greatly increased, but paradoxically 
blockade of ICOS only during the effector phase, improves clinical scores (64, 
65). This points to a more complex role of the ICOSL:ICOS pathway in T cell 
regulation, perhaps shifting the balance towards IL-4/IL-10 and humoral at the 
expense of IFN-γ-mediated cytotoxic/TH1 responses (64). In addition, 
stimulating IL-10 production may contribute to the regulation of 
immunosuppressive Tregs and T cell tolerance (66, 67). It has been proposed 
that ICOSL expression by melanoma cells might drive the activation and 
expansion of Tregs as a mechanism of immune evasion (68), but altogether 
evidence for the expression of ICOSL on other solid tumors is still sparse. 
PD1 and its ligands. Whereas PD-L2 is induced by cytokines mainly on 
macrophages and DCs (69, 70), PD-L1 is expressed more widely by B, T, 
myeloid cells and DCs as well as non-lymphoid tissues (71-74) and a variety 
of tumors (75, 76). The PD-1 receptor is upregulated on CD4+ and CD8+ T 
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cells, B cells, and monocytes upon activation (77). PD-L1 and PD1 expression 
appear to be associated with poorer outcome in several tumors (78-81) and 
their interactions have an important inhibitory function in controlling 
inflammatory responses in peripheral tissues. PD-L1:PD1 signaling may 
participate in functionally inactivating ‘exhausted’ virus-specific CD8+ T cells 
during chronic viral infections (82, 83). Furthermore, PD-1 deficient mice 
develop lupus-like autoimmune diseases suggesting that PD-1 is involved in 
the maintenance of peripheral self-tolerance (84).	  
The immune system is not excluded from the CNS, but both are linked and 
immune responses tightly regulated to protect the nervous tissue from 
irreparable injury. One of our major interests during the last years was to 
study the immunoregulatory properties of infiltrating APCs and resident glial 
cells in controlling T cell effector functions within the CNS in the context of GB 
and MS. We focused on the B7:CD28 co-stimulatory pathway, given that its 
manipulation is an attractive strategy to either enhance tumor immunogenicity 
or control autoimmune inflammation. Subsequently, we have used conditional 
gene targeting approaches to better understand how glial cells contribute to 
the tissue homeostasis of the healthy CNS beyond APC functions and co-
inhibition, concentrating on astrocytes. 
 
RESULTS AND DISCUSSION 	  
Expression of B7 checkpoint molecules by glioblastoma 
 
I. Schreiner B, Wischhusen J, Mitsdoerffer M, Schneider D, Bornemann A, Melms A, 
Tolosa E, Weller M, Wiendl H (2003) Expression of the B7-related molecule ICOSL 
by human glioma cells in vitro and in vivo. Glia. 44(3):296-301 
 
II. Wintterle S*, Schreiner B*, Mitsdoerffer M, Schneider D, Chen L, Meyermann R, 
Weller M, Wiendl H (2003) Expression of the B7-related molecule B7-H1 by glioma 
cells: a potential mechanism of immune paralysis. Cancer Res. 63(21):7462-7 
 
GB is a highly aggressive brain cancer with poor clinical prognosis despite 
surgery, radiation and chemotherapy (reviewed in (85)). GB are exemplary for 
their ability to suppress effective antitumor responses and actively exploit 
some of the same immune inhibitory mechanisms that form the basis of the 
CNS ‘immune privilege’ described above (reviewed in (86, 87). Given the 
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failure of conventional treatment in GB, immunotherapeutic strategies to 
enhance the immunogenicity of GB cells are amongst the most promising. In 
particular manipulations of signal 2 immune checkpoint molecules, such as 
the B7 family members, to augment antitumor T-cell responses are being 
tested (reviewed in (88)). 
 
The goal of our first study described here (study I) was to analyze in detail the 
expression of ICOSL in biopsy specimens of patients with GB or anaplastic 
oligoastrocytoma and human malignant glioma cell lines. 3 out of 4 malignant 
glioma tissue samples stained positive for ICOSL protein by 
immunohistochemistry. ICOSL could be detected on more than 90% of tumor 
cells and positive cells were evenly scattered throughout the specimen. Of 
note, endothelial cells of blood vessels were also ICOSL+. In contrast, no 
ICOSL was found in normal brain tissue adjacent to tumor tissue or in one 
brain biopsy specimen without pathological alterations. In addition, ICOSL 
protein and mRNA was expressed in 7 of 12 glioma cell lines. Its expression 
was upregulated by the inflammatory cytokine tumor necrosis factor (TNF)-α 
but not IFN-γ. Neutralizing ICOSL by blocking antibodies in co-cultures of 
glioma cells with alloreactive peripheral blood leukocytes or T cell subsets 
(CD4+ and CD8+) reduced TH1 and TH2 cytokine levels in vitro. However, 
ICOSL gene transfer into glioma cells did not alter their immunogenicity as 
determined by alloreactive co-culture assays. 
At this point, we did not continue to investigate the cytokine milieu and 
presence of ICOS+ Tregs in GB samples in more detail. However, in the light 
of recent studies suggesting that ICOSL expression by melanoma may drive 
ICOS+ Tregs in the tumor microenvironment (68, 89), it would be interesting to 
determine the levels of ICOSL in a larger number of GB samples and to 
correlate its expression with tumor-infiltrating Treg numbers and survival. In 
addition, it has been reported that the frequency of intracranial Tregs was 
reduced in GL261 glioma-bearing ICOS-deficient compared to wildtype mice, 
providing rationale for further investigations (90). 
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Instead we focused in a second study on the B7 homologue PD-L1, which 
binds the strong negative regulator of T cell activation PD-1 (study II). 
Immunohistochemical analysis of malignant glioma specimens revealed 
strong PD-L1 immunoreactivity in all 10 samples examined, including 9 GB 
and 1 mixed glioma specimens.	  More than 50% of the tumor cells expressed 
PD-L1 in the GB sections (range from 50 to 90%). In contrast, no PD-L1 was 
found in brain tissue adjacent to tumor tissue or in a normal brain biopsy 
specimen. Although lacking B7.1/2 (CD80/86), all 12 glioma cell lines 
constitutively expressed PD-L1 mRNA and protein. Exposure to IFN-γ 
strongly enhanced PD-L1 expression (Figure 1). 
Figure 1. (A-C) Analysis of PD-L1 (B7-H1) expression in brain tumor specimens. Frozen tissue sections 
of a GB (A and B), normal brain (C), or human thymus (D) were immunostained with the PD-L1-specific 
mAb 5H1 (A, C, and D) or IgG isotype control (B). Human thymus served as a positive control (D). A-C, 
×200; D, ×400. (E) n PD-L1 protein expression at the cell surface of different human glioma cell lines 
cultured with and without IFN-γ (500 U/ml for 48 hrs) was determined by flow cytometry. The numbers 
indicate the specific fluorescence index (SFI).   Isotype control antibody staining. Adapted from	  (91). 
 
To investigate in which ways glioma-associated PD-L1 was functional, we 
performed coculture experiments of glioma cells with alloreactive CD4+ and 
CD8+ T cells. The LN-229 glioma cell line used for this set of experiments, 
exhibited high constitutive levels of human leukocyte antigen (HLA) class I 
and HLA-DR antigens in addition to PD-L1 but did not express CD80 and 
CD86.	   PD-L1 antibody blockade increased CD4+ as well as CD8+ T-cell 
cytokine production (IFN-γ, interleukin (IL)-2, and IL-10) and levels of the T-
cell activation marker CD69, and thereby pointed to a strong inhibitory 
function of glioma-related PD-L1 on T-cell stimulation. 
 
E
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We concluded that PD-L1 expression may significantly influence the outcome 
of GB-T cell interactions and may represent an, at that time, novel mechanism 
by which glioma cells evade immune recognition and destruction. Since then, 
the main results of this study have been confirmed by several other groups: 
PD-L1 expression has been demonstrated on established GB cell lines, 
primary tumors and in addition has been correlated with malignancy tumor 
grade (92-95). In a study by Parsa and colleagues loss of phosphatase and 
tensin homologue (PTEN) function was linked to PD-L1 expression and 
immunoresistance in glioma (96). Moreover, a considerable percentage of 
tumor-infiltrating lymphocytes from malignant glioma stained positive for PD-1 
(93). Immune-based therapies blocking PD-L1 and PD-1 have achieved 
promising antitumor activity for solid tumors and leukemia patients in the last 
years (97-99), and clinical trials evaluating this approach in GB patients are in 
development or underway (ClinicalTrials.gov Identifier: NCT02017717 (phase 
III), NCT01952769 (phase I/II); reviewed in (86)). 
 
The role of PD1 ligands on different myeloid cell subsets/microglia in 
autoimmune CNS inflammation 	  
III. Schreiner B*, Mitsdoerffer M*, Kieseier BC, Chen L, Hartung HP, Weller M, 
Wiendl H (2004) Interferon-beta enhances monocyte and dendritic cell expression of 
B7-H1 (PDL1), a strong inhibitor of autologous T-cell activation: relevance for the 
immune modulatory effect in multiple sclerosis. J Neuroimmunol. 155(1-2):172-82 
 
IV. Schreiner B, Bailey SL, Shin T, Chen L, Miller SD (2008) PD-1 ligands 
expressed on myeloid-derived APC in the CNS regulate T cell responses in EAE. 
Eur J Immunol. 38(10): 2706-17 
 
MS is an autoimmune demyelinating disease of the brain and spinal cord. In 
most patients, the initial disease course is relapsing-remitting, as inflammatory 
attacks and neurological deficits are followed by periods of recovery. The 
disease frequently leads to a continuous and irreversible deterioration in 
neurologic function termed secondary-progressive MS. The aetiology of MS 
probably involves both a complex genetic component, in which multiple 
susceptibility genes are important, and several environmental factors (100-
102). In MS myeloid APCs are thought to present myelin epitopes to 
autoreactive T cells in the periphery and CNS (35, 103), and thereby 
propagate an autoimmune inflammatory attack that ultimately overrides local 
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mechanisms of the CNS ‘immune privilege’. As PD-1:PD-L1 interactions are 
important in inhibiting initial self-reactive T cell activation and expansion but 
also subsequent T cell effector functions in the target organ (reviewed in 
(104)), their re-enforcement may be a successful strategy to ameliorate 
autoimmune diseases including MS. 
 
We therefore investigated the expression and regulatory function of PD-L1 on 
monocytes in the peripheral blood of healthy subjects and MS patients, and its 
modulation by the approved MS drug IFN-ß (study III). Although there were 
only low quantities of PD-L1 on unstimulated human monocytes, its 
expression was strongly upregulated by IFN-ß and led to reduced APC 
functions in vitro. In particular blocking PD-L1 on monocytes markedly 
increased their capacity to stimulate secretion of cytokines (IL-2 and IFN-γ) by 
and proliferation of glatiramer acetate- (a random polymer of four amino acids 
found in myelin basic protein, MBP) or superantigen-activated autologous 
CD4+ T cells. Monocytes from healthy subjects and untreated patients with 
MS had similar baseline levels and inducibility of PD-L1 in response to IFN-ß 
in vitro. Moreover, MS patients treated with IFN-ß in vivo for 6 months had 8-
fold more PD-L1 mRNA transcripts than before treatment (Figure 2). 
 
Figure 2. Modulation of PD-L1 (B7-H1) expression by IFN-ß in MS patients in vitro and ex vivo. (A) PD-
L1 mRNA (upper row) or protein (lower row) was measured by qRT-PCR and flow cytometry on 
monocytes of healthy donors (HD) and in MS patients. Cells were cultured without or in the presence of 
IFN-ß (1000 U/ml) or IFN-γ (500 U/ml; positive control) for 48 hrs. The box plots show the median, 
quartiles and minimum-maximum rations of copy numbers of PD-L1 relative to the 18S housekeeping 
gene (mRNA), or SFI values (protein). ** p<0.01 (ANOVA and subsequent post hoc tests). (B) PD-L1 
expression was determined by qRT-PCR in PBMC of MS patients before (n=9) and 6 months after (n=9) 
initiation of IFN-ß1b treatment (8 MIU s.c. every other day). Basal mRNA levels of one donor were set to 
1 and the remaining mRNA levels were related to this. Arrows indicate medians (*p<0.05, two-sided t-
test). Adapted from (105). 
A B
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Our results suggested that the anti-inflammatory effect of IFN-ß treatment was 
partially due to PD-L1 expression. We concluded that therapies that aim to 
increase PD-L1 expression on monocytes/APCs might be a promising 
approach to treat MS. On this note, PD-L1 fusion protein therapeutics have 
been recently tested in experimental models of collagen-induced arthritis and 
colitis where they appear to have protective effects (106, 107). 
 
To study the role of PD-L1 expression on different infiltrating and resident 
myeloid cells/APCs in regulating local T-cell function in the CNS itself, we took 
advantage of the relapsing PLP-peptide/SJL and chronic MOG-
peptide/C57BL/6 EAE model (reviewed in (108); study IV). Despite limitations, 
EAE has proven very useful to examine inflammatory aspects of MS and 
develop new therapeutic concepts as it shares many immunopathological 
characteristics with the human disease. Using this model, Latchman and 
colleagues had previously shown that transfer of wild-type encephalitogenic T 
cells into PD-L1-deficient recipient mice exacerbated EAE which already 
hinted to a critical function for PD-L1 in limiting pathogenic effector T cells 
responses in the target tissue (109). Therefore our first aim was to dissect the 
expression pattern of PD-1 ligands on myeloid APC cell types in the CNS 
during acute EAE. PD-L1 and PD-L2 were differentially expressed on discrete 
APC populations in the inflamed CNS with high PD-L1 levels on 
macrophages, monocyte-derived DCs and microglia. Increased PD-L1 
expression in the CNS during EAE was attributable to the infiltration of PD-L1+ 
myeloid cells and up-regulation on microglia. Our data demonstrated that the 
majority of CNS CD4+ T cells isolated from the inflamed nervous tissue during 
acute EAE were PD-1+, and T cells specific for relapse-associated myelin 
epitopes expressed PD-1 upon antigen stimulation in the CNS. PD-L1 and 
PD-1 had mainly inhibitory functions on CNS T cells. PD-L1 negatively 
regulated the stimulation of activated PD-1+ TH cells in co-cultures with 
microglia and different CNS-infiltrating APCs presenting endogenously 
processed peptides. The preponderance of IFN-γ+ versus IL-17+ T cells in the 
CNS of PD-L1-/- mice suggested that PD-L1 more selectively suppresses TH1 
than TH17 responses in vivo. In contrast, blockade of PD-L2 had less 
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pronounced regulatory effects (Figure 3). Overall, the results suggested that 
local PD-L1:PD-1 interactions attenuated autoreactive T cell responses 
thereby restricting immunopathological damage in the CNS. 
 
Figure 3. (A) Expression of PD-L1 (B7-H1) and PD-L2 (B7-DC) on microglia and different CNS-
infiltrating APC subsets in the inflamed CNS. Cells were isolated from PLP178-191-primed mice at the 
peak acute phase of relapsing EAE (day 14-15 post-immunization) and stained for flow cytometry with 
PD-L1, PD-L2 and the following markers: Macrophages were CD45highCD11c-CD11b+, microglia were 
CD45lowCD11b+, monocyte-derived DCs (mDCs) were CD45highCD11c+CD11b+ and CD11b-DC were 
CD45highCD11c+CD11b-. Data are plotted as mean percentage ±SEM from at least 3 independent 
experiments. Gates were set respective to isotype controls. (B) The frequency of IFN-γ-producing cells 
was determined by ELISPOT from the pooled CNS of PLP178-191-primed SJL mice (n=5-10) at the peak 
acute phase of relapsing EAE. Endogenous presentation (i.e. without addition of exogenous PLP-
petides) was determined in the presence of blocking antibodies to PD-L1, PD-1 or isotype controls. Data 
are representative of 4 independent experiments. * p<0.05 (unpaired t-test). Adapted from (110). 
 
Our work confirmed results of a second study (111) that identified 
microglia/macrophages and invading T cells as the main cellular source of 
inhibitory PD-L1 in the inflamed CNS tissue during EAE. In addition, in vitro 
exposure of human monocytes and microglial cells to TH1 cell-derived 
supernatants significantly upregulated PD-L1 mRNA (111). In the meantime 
PD-L1 has also been detected on Iba-1+ macrophage/microglia and GFAP+ 
astrocytes mostly in sub-/acute MS lesions but also in normal-appearing white 
matter of specimens from MS patients (112, 113), which emphasizes the 
therapeutic potential of PD-L1:PD-1 modulation in human neuroinflammatory 
diseases. 
  
A B
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Homeostatic functions of GFAP+ astrocytes 	  
V. Schreiner B, Romanelli E, Liberski P, Ingold-Heppner B, Sobottka-Brillout B, 
Hartwig T, Chandrasekar V, Johannssen H, Zeilhofer HU, Aguzzi A, Heppner F, 
Kerschensteiner M, Becher B (2015) Astrocyte depletion impairs redox homeostasis 
and triggers neuronal injury in the adult CNS. Cell Reports. doi: 
10.1016/j.celrep.2015.07.051. [Epub ahead of print] PMID: 26299968 
 
There is accumulating evidence, that glial cells including astrocytes exert a 
broad control of CNS tissue homeostasis besides their engagement in cross-
talk with CNS-infiltrating T cells (48). As discussed in the introductory part 
above, in vitro studies with isolated cells or brain slices have taught us much 
about basic properties of astrocytes. However, our knowledge of maintenance 
functions of astrocytes in the adult CNS under physiological conditions in vivo 
is still incomplete (study V). 
Therefore, we decided to use a model by which tamoxifen-inducible Cre-
ERT2 allows temporarily precise postnatal induction of diphtheria toxin-A 
(DTA) in GFAP+ astrocytes (GFAPCreERT2:DTA model (114, 115)). DT is a 
toxin that, upon entry into the cytoplasm, ’paralyzes’ target cells by catalyzing 
the inactivation of elongation factor 2, resulting in termination of protein 
synthesis and subsequent cell death (116). We confirmed the specificity of 
this genetic targeting approach by flow cytometry and immunohistochemical 
analysis of GFAPCreERT2 mice crossed to a Rosa26-tdTomato reporter 
mouse line (Figure 4A). In the spinal cord, the Cre-recombinase was primarily 
active in the subpopulation of GFAP+ astrocytes whereas only a smaller 
fraction of astrocytes labeled with the more-abundant marker S100+ were 
targeted (Figure 4B). At day 6 after the start of tamoxifen treatment, the 
expression of DTA led to significantly reduced tdTomato+ cell numbers 
compared to controls (Figures 4B and C). This suggested that a substantial 
fraction of GFAP+ astrocytes, in which the Cre recombinase was active, were 
dying or arrested in an inanimate state with blocked (reporter) protein 
synthesis. 
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Figure 4. (A) Schematic diagram of GFAPCreERT2 × DTA (GFAPCreERT2:DTA) mice, crossed with 
Rosa26-tdTomato transgenic reporter mice (Ai14) to label cells in which Cre-mediated recombination 
takes place. Tamoxifen i.p. injections were performed at days 1-5. (B and C) Spinal cord samples were 
immunostained for GFAP and S100, and the numbers of tdTomato+ cells as well as their co-localization 
with the astrocyte marker proteins were quantified. (B) Representative images of tdTomato+ cells in 
sections from control GFAPCreERT2:tdTomato mice and mice in which the DTA expression 
is additionally activated (GFAPCreERT2:DTA:tdTomato) are shown. The insets show tdTomato+ cells 
with astrocytic morphology and co-localizing with GFAP. The number of tdTomato+ astrocytes per 
section were significantly reduced at day 6 in GFAPCreERT2:DTA:tdTomato-D6 compared to 
GFAPCreERT2:tdTomato-Ctrl mice. For quantifications, see (C). In (C), squares and circles represent 
individual mice and the bar the mean value (n = 3/group; two-tailed Student’s t test). The scale bars 
represent 200 µm (B) and 50 µm (inset in B). Adapted from (117). 
 
As the most-pronounced pathology in tamoxifen-treated GFAPCreERT2:DTA 
mice was found in the cervical spinal cord, our subsequent analysis focused 
on this region. i.p. injections of tamoxifen in GFAPCreERT2:DTA mice 
resulted in a rapid and severe paresis that started asymmetrically in both 
upper limbs, later progressed to all four extremities (onset at days 5-8), and 
was accompanied by weight loss (Figure 5A). In the spinal cord, we found 
that the numbers of neurons and oligodendrocytes were reduced at day 6, 
paralleling the appearance of the clinical phenotype. In contrast, a 
comparable number of S100+ astrocytes (of which only few express the Cre 
recombinase and the loss of which is therefore likely obscured by a gliotic 
response) was present at all time points, suggesting that an overall astroglial 
support structure persisted (Figures 5B and C). Moreover, neuronal injury 
occurred in the absence of any major microvascular damage and microbleeds 
or leakage of toxic blood products. 
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Figure 5. Paralysis of Astrocytes in GFAPCreERT2:DTA Mice leads to a rapid and severe neuronal 
motor phenotype. (A-C) GFAPCreERT2:DTA mice were i.p. injected with tamoxifen at days 1–5. (A) At 
days 5–8, mice exhibited a severe paralysis that rapidly progressed to all four limbs and was 
accompanied by weight loss (mean ± SEM; n = 3-7/group; two-way ANOVA test). (B and C) Cervical 
sections were immunostained at the indicated time points to assess remaining astrocyte structural 
integrity (S100) and to detect neurons (NeuN), oligodendrocytes (APC-CC1), and microglia (Iba1). 
Arrows in (B) indicate neurons undergoing cell death. For quantifications, see (C). Values of individual 
mice are shown by circles (GFAPCreERT2:DTA; n = 4-7 mice/time point) and squares (CreERT2- 
control tissue; n = 4). Group means are indicated by bars. Statistical analyses were performed via one-
way ANOVA and Dunnett’s multiple comparison test versus Ctrl. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 
0.001.The scale bar represents 50 µm (B). Adapted from (117). 
 
Given the observed morphological activation and proliferation of microglia 
(Figures 5B and C), we examined whether microglial-derived factors 
contributed to neuronal demise and the functional deficits in 
GFAPCreERT2:DTA mice. To directly assess the role of microglia in 
astrocyte-driven motoneuron injury in our model, we used the colony-
stimulating factor 1 receptor (CSF1R) antagonist PLX5622, which has been 
shown to efficiently eliminate microglia from the adult brain	   (118). CSFR1 
blockade decreased microglial content as assessed by the number of Iba1+ 
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cells in cervical sections (Figures 6A and B). However, at the same time 
point, the loss in motoneuron numbers (Figures 6A and B) and the severity 
of clinical paralysis (Figure 6C) was not significantly different from mice fed 
with control chow. These findings indicated that, in our model, microglia are 
rather bystanders and their activation had no impact on neuronal loss and 
clinical decline. 
Figure 6. Motoneuron loss in spinal cords of GFAPCreERT2:DTA mice is independent of microglial 
bystander activation. GFAPCreERT2:DTA (n = 9/group) and CreERT2-control mice (n = 4 to 5/group) 
were pre-/treated with the oral CSF1R inhibitor PLX5622 (1.2 g/kg chow) or vehicle for 1 week to 
eliminate microglia and kept on this diet throughout the experiment. (A) Representative Iba1 and NeuN 
immunofluorescent stainings from the anterior horn region at day 5 of tamoxifen i.p. application showing 
loss of moto-/neurons despite robust decreases in microglial numbers. (B) Quantifications of Iba1+ and 
motoneuron cell bodies. (C) There was no statistical difference in paralysis scores at day 5 between 
PLX5622- and vehicle-treated GFAPCreERT2:DTA mice. Mice were pooled from two independent 
experiments, and asterisks indicate significance by unpaired Student’s t test; ∗p < 0.05; ∗∗∗p < 0.001. 
Error bars represent mean ± SEM. The scale bars represent 100 µm (A). Adapted from (117). 
 
Although the acute inhibition of astrocyte protein synthesis might result in the 
lack of trophic support for neurons, we reasoned that it was equally likely that 
it led to inactivation of critical glial-detoxifying pathways. Mutations in 
superoxide dismutase 1 (SOD1) cause a rare form of fALS, and studies using 
transgenic rodents expressing mutant human SOD1 have indeed 
demonstrated that motoneurons are particularly vulnerable to toxic activity 
mediated by astrocytes	   (119, 120). In addition, previous co-culture 
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experiments suggested that neurons depend on the antioxidant potential of 
astrocytes for their own defense against oxidative stress in vitro (121). To 
assess the redox-scavenging capacity in the GFAP+ astro-/glial cell pool in 
our in vivo model, we measured the mRNA and protein expression of different 
ROS-detoxifying enzymes. We detected diminished ROS-scavenging 
capabilities in the glial pool in GFAPCreERT2:DTA mice which were 
accompanied by increased superoxide levels and enhanced oxidative DNA 
damage in the spinal cord tissue. Reactive oxygen and nitrogen species 
(ROS/RNS) scavenger treatment of mice (122) significantly increased the 
number of surviving neurons including a preservation of motoneurons. In 
addition, we measured serum concentrations of neuron-specific enolase 
(NSE), which is systemically released upon neuronal injury. NSE serum levels 
in GFAPCreERT2:DTA mice were significantly increased compared to 
CreERT2- controls with mean NSE levels lying between values reported for 
models of ischemic stroke and inflammatory CNS insults (123). Again 
treatment with ROS/RNS scavengers reduced serum NSE levels significantly. 
ROS/RNS scavenging not only improved neuronal survival but also prevented 
clinical deficits (at days 5 or 6). 
Collectively, our results emphasized the magnitude to which neuronal viability 
depends on the functional integrity of astrocytes in the adult CNS. They 
suggested that the subpopulation of GFAP+ astrocytes maintained neuronal 
health by controlling redox homeostasis in the adult CNS. This could have 
implications not only for neurodegenerative diseases like ALS, but also for 
neuroprotective interventions, that might be more likely to fail if they do not 
also target the glial, metabolically active environment of neurons. 
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CONCLUSIONS AND OUTLOOK 	  
It is becoming apparent that the CNS environment allows immune responses 
within its borders to fight tumors and pathogens but local control processes 
involving resident glial cells are critical to protect vulnerable nervous tissue. In 
addition, it is increasingly appreciated that glial cells in particular astrocytes 
have diverse maintenance functions both in the inflamed CNS but also under 
non-pathological conditions that reach far beyond pure scar formation and 
structural support. An improved understanding of mechanisms of glial immune 
regulation and homeostatic functions is a key requirement for the 
advancement of therapeutic neuroprotective strategies. Here, we uncover the 
PD-L1:PD-1 pathway as an important component of the local immune 
signaling networks that restrict immune responses, and identify the redox 
scavenging capabilities of the astroglial cell pool as a critical factor for 
maintaining neuronal health in the adult CNS. 
We have learnt during our studies, that there is a considerable heterogeneity 
in the population of astroglia. Distinct astrocyte subsets may differ in their 
impact on the pathogenesis of MS during different disease stages. In the 
future, we therefore attempt to further characterize astroglial cell phenotypes 
and glial-derived molecules that contribute to the immunopathology of 
inflammatory CNS diseases such as MS. 	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